1.A comparison of the acute antiemetic effect of ondansetron with combination of metoclopramide, dexamethasone, lorazepam in patients receiving cisplatin.
Seung Ho BAICK ; Mi Kyung CHA ; Yong Wook CHO ; Do Yeun OH ; Sun Joo KIM
Journal of the Korean Cancer Association 1992;24(5):759-765
No abstract available.
Antiemetics*
;
Cisplatin*
;
Dexamethasone*
;
Humans
;
Lorazepam*
;
Metoclopramide*
;
Ondansetron*
2.Two Cases of Deep Vein Thrombosis Associated with Behcet's Disease.
Hong Suk KIM ; Sung Nam CHANG ; Eun Sun CHOI ; Doyeun OH ; Wook Hwa PARK
Korean Journal of Dermatology 2000;38(1):95-98
In Behcet's disease(BD), there is a marked increase in vascular complication. Venous thrombosis is a major feature of the disease, although arterial thrombosis is rarely described. In Behcet's disease, thrombosis occurs in 20 to 30% of patients. We present two cases of Behcet's disease admitted to our hospital whose chief complaint was progressive increases in swelling and pain in their legs. In the first case, routine coagulation tests and sero-immunological tests were within normal limits, however, protein C and S activity were significantly decreased in the patient. So these findings suggest that auto-immune acquired protein S deficiency may be involved in the pathogenesis of thrombotic events in BD.
Humans
;
Leg
;
Protein C
;
Protein S Deficiency
;
Thrombosis
;
Venous Thrombosis*
3.The Transfection of Cytosine Deaminase Gene and the Cell Killing Effects of Administration of 5-Fluorocytosine in Colon Cancer Cell Lines.
Journal of the Korean Surgical Society 2004;66(4):271-280
PURPOSE: Among cancer gene therapies, the aims to eliminate malignant cells using genes as drugs as substitutes for conventional therapy, the use of bacterial cytosine deaminase (CD) which can convert the nontoxic 5-fluorocytosine (5-FC) to toxic 5-fluorouracil (5-FU), has been reported to provide a useful system for the selective killing of gene- modified mammalian tumor cells. Recently the transfection and expression of the CD gene, and the toxicity of 5-FC in eukaryotic cells, have been reported in colon, prostate and breast cancers, as well as in glioblastomas. To evaluate the growth inhibition effects in WiDr and LoVo colorectal cancer cells, after CD gene transfection and 5-FC administration, for the selective killing of cancer cells. METHODS: WiDr and LoVo colon cancer cell lines were cultured and the absorbencies for the percentage survival, on days 2, 4, 6, 8, and 10 of the culture, estimated by the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetra-zolium bromide (MTT) test. The experimental subjects were divided as follows; Group 1: administration of 5-FC only, Group 2: administration of 5-FU only, Group 3: administration of 5-FC after CD gene transfection using pCMV/CD-1 plasmid vector. Each experiment, on days 2, 4, 6, 8 and 10 of the culture after the administration of 5-FC or 5-FU concentration of 10, 100 and 1000 uM, was triplicated and calculated the mean with standard deviation. The bacterial CD gene was transfected into each cell lines, using the lipofectin method, and the transfection and expression of the CD protein identified with beta-galactosidase immunohistochemical staining and western blotting. The growth inhibition effects in group 3 were compared with those in group 1 and 2, and the bystander effects and cell recoveries, after finishing the 5-FC treatment, evaluated until day 20 of the culture. RESULTS: The calculated survival percentages by from the MTT tests in the WiDr and LoVo cells revealed 110~150% enhancing effects after the administration of 5-FC concentration of 10, 100 and 1000micro M (group 1), and 30~90% after the administration of 5-FU at the same concentrations (group 2), which were shown to be statistically significantly (P<0.001). After transfection of pCMV/CD-1 plasmid vector into the WiDr and LoVo cells using the lipofectin method, the transfection rate of the WiDr and LoVo cells were 4.2 +/- 0.6% and 13.8 +/- 0.8%, respectively. Also the CD protein, with the polyclonal anti-CD antibody, by western blot, revealed weak expression on day 2, followed by strong expression on day 4, which progressively decreased by days 6 and 8 in the WiDr cells. Conversely, the LoVo cells showed weak expression on day 2, which progressively increased by days 4 and 6, was followed by the strongest expression on day 8 in LoVo cells. About 60~85% significant growth inhibition effects (P<0.001) were revealed in group 3, with proportionally different effects, corresponding to the CD gene transfection rate, concentration of 5-FC and duration of the culture. The 60~85% growth inhibition effects were complex of the response to the transfection rate and the bystander effects of CD expressed cells to the CD non-expressed cells. CONCLUSION: From our results, the administration of 5-FC after CD gene transfection revealed statistically significant growth inhibition effects of 60~85%, which were complex of the effects of CD expressed cells and the bystander effects to the CD non-expressed cells, and proportionally corresponding to the transfection rate, the duration of the CD protein expression and the concentration of 5-FC.
beta-Galactosidase
;
Blotting, Western
;
Breast
;
Bystander Effect
;
Cell Line*
;
Colon*
;
Colonic Neoplasms*
;
Colorectal Neoplasms
;
Cytosine Deaminase*
;
Cytosine*
;
Eukaryotic Cells
;
Flucytosine*
;
Fluorouracil
;
Genes, Neoplasm
;
Glioblastoma
;
Homicide*
;
Plasmids
;
Prostate
;
Transfection*
4.The Transfection of Cytosine Deaminase Gene and the Cell Killing Effects of Administration of 5-Fluorocytosine in Colon Cancer Cell Lines.
Journal of the Korean Surgical Society 2004;66(4):271-280
PURPOSE: Among cancer gene therapies, the aims to eliminate malignant cells using genes as drugs as substitutes for conventional therapy, the use of bacterial cytosine deaminase (CD) which can convert the nontoxic 5-fluorocytosine (5-FC) to toxic 5-fluorouracil (5-FU), has been reported to provide a useful system for the selective killing of gene- modified mammalian tumor cells. Recently the transfection and expression of the CD gene, and the toxicity of 5-FC in eukaryotic cells, have been reported in colon, prostate and breast cancers, as well as in glioblastomas. To evaluate the growth inhibition effects in WiDr and LoVo colorectal cancer cells, after CD gene transfection and 5-FC administration, for the selective killing of cancer cells. METHODS: WiDr and LoVo colon cancer cell lines were cultured and the absorbencies for the percentage survival, on days 2, 4, 6, 8, and 10 of the culture, estimated by the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetra-zolium bromide (MTT) test. The experimental subjects were divided as follows; Group 1: administration of 5-FC only, Group 2: administration of 5-FU only, Group 3: administration of 5-FC after CD gene transfection using pCMV/CD-1 plasmid vector. Each experiment, on days 2, 4, 6, 8 and 10 of the culture after the administration of 5-FC or 5-FU concentration of 10, 100 and 1000 uM, was triplicated and calculated the mean with standard deviation. The bacterial CD gene was transfected into each cell lines, using the lipofectin method, and the transfection and expression of the CD protein identified with beta-galactosidase immunohistochemical staining and western blotting. The growth inhibition effects in group 3 were compared with those in group 1 and 2, and the bystander effects and cell recoveries, after finishing the 5-FC treatment, evaluated until day 20 of the culture. RESULTS: The calculated survival percentages by from the MTT tests in the WiDr and LoVo cells revealed 110~150% enhancing effects after the administration of 5-FC concentration of 10, 100 and 1000micro M (group 1), and 30~90% after the administration of 5-FU at the same concentrations (group 2), which were shown to be statistically significantly (P<0.001). After transfection of pCMV/CD-1 plasmid vector into the WiDr and LoVo cells using the lipofectin method, the transfection rate of the WiDr and LoVo cells were 4.2 +/- 0.6% and 13.8 +/- 0.8%, respectively. Also the CD protein, with the polyclonal anti-CD antibody, by western blot, revealed weak expression on day 2, followed by strong expression on day 4, which progressively decreased by days 6 and 8 in the WiDr cells. Conversely, the LoVo cells showed weak expression on day 2, which progressively increased by days 4 and 6, was followed by the strongest expression on day 8 in LoVo cells. About 60~85% significant growth inhibition effects (P<0.001) were revealed in group 3, with proportionally different effects, corresponding to the CD gene transfection rate, concentration of 5-FC and duration of the culture. The 60~85% growth inhibition effects were complex of the response to the transfection rate and the bystander effects of CD expressed cells to the CD non-expressed cells. CONCLUSION: From our results, the administration of 5-FC after CD gene transfection revealed statistically significant growth inhibition effects of 60~85%, which were complex of the effects of CD expressed cells and the bystander effects to the CD non-expressed cells, and proportionally corresponding to the transfection rate, the duration of the CD protein expression and the concentration of 5-FC.
beta-Galactosidase
;
Blotting, Western
;
Breast
;
Bystander Effect
;
Cell Line*
;
Colon*
;
Colonic Neoplasms*
;
Colorectal Neoplasms
;
Cytosine Deaminase*
;
Cytosine*
;
Eukaryotic Cells
;
Flucytosine*
;
Fluorouracil
;
Genes, Neoplasm
;
Glioblastoma
;
Homicide*
;
Plasmids
;
Prostate
;
Transfection*
5.Primary mesenteritis: a case report.
Seong Jae CHA ; Hyun Muck LIM ; Sun Taik CHANG ; Yong Wook PARK ; Jae Hyung YOO ; Key Yong SONG
Journal of the Korean Surgical Society 1991;41(6):819-829
No abstract available.
6.Uterine Artery Embolization for the Treatment of Symptomatic Fibroids.
Kyung Ah KIM ; Man Deuk KIM ; Hee Jin KIM ; Mee Hwa LEE ; Jin Ho CHO ; Sun Hee CHA ; Sang Wook YOON ; Eun Hee AHN
Journal of the Korean Radiological Society 2005;52(6):401-407
PURPOSE: The aim of this study was to determine the potential usefulness of uterine artery embolization (UAE) for the management of uterine leiomyoma. MATERIALS AND METHODS: Sixty nine patients (mean age; 40.3 years, age range; 31-52 years) who underwent UAE for symptomatic fibroids (with menorrhagia, dysmenorrhea and bulk-related symptoms) from January 2000 to December 2000 were retrospectively analyzed. The mean follow-up period was 3.5 months (range: 1-8 months). The fibroids ranged in size from 2.0 cm to 13.2 cm with a mean size of 5.8 cm. We performed embolization using polyvinyl alcohol particles (250-710microgram). The improvement of the clinical symptoms was analyzed. Reduction of the uterine and predominant fibroid volumes was assessed using MRI. RESULTS: Symptom improvement for the menorrhagia (87.5%), dysmenorrhea (83.3%) and the bulk-related symptoms (79.2%) was reported. Complications included ovarian failure in four patients (5.8% of the total patients, mean age: 43.3 yrs) and infection in three patients (4.3% of the total patients) who underwent conservative management with intravenous antibiotics and analgesics. The volume reduction rate of the uterus and the predominant fibroids after uterine artery embolization were 36.3% and 56.6%, respectively. CONCLUSION: UAE is a promising new treatment for symptomatic fibroids and may be a valuable alternative to hysterectomy.
Analgesics
;
Anti-Bacterial Agents
;
Dysmenorrhea
;
Female
;
Follow-Up Studies
;
Humans
;
Hysterectomy
;
Leiomyoma*
;
Magnetic Resonance Imaging
;
Menorrhagia
;
Polyvinyl Alcohol
;
Retrospective Studies
;
Uterine Artery Embolization*
;
Uterine Artery*
;
Uterus
7.A Case of Coronary Artery Aneurysm after Sirolimus-Eluting Stent Implantation.
Kyung Sun PARK ; Sung Tae CHA ; Jung Hoon SUNG ; In Jae KIM ; Sang Wook LIM ; Dong Hoon CHA
Korean Circulation Journal 2007;37(3):127-129
This report describes the case of a 26-year-old male diagnosed with angina on exertion. A diagnostic coronary angiography revealed significant luminal narrowing at the middle third of the left anterior descending artery and proximal circumflex artery. The patient underwent implantation of sirolimus-eluting stents. Eight months after implantation of the stents, a follow-up coronary angiography showed intrastent coronary artery aneurysms. We suggest that the implantation of the sirolimus-eluting stent caused late formation of a coronary artery aneurysm.
Adult
;
Aneurysm*
;
Arteries
;
Coronary Aneurysm
;
Coronary Angiography
;
Coronary Vessels*
;
Follow-Up Studies
;
Humans
;
Male
;
Phenobarbital
;
Sirolimus
;
Stents*
8.Characterization of a prenatally diagnosed de novo der(X)t(X;Y)(q27;q11.23) of fetus.
Sang Hee PARK ; Sung Han SHIM ; Yong Wook JUNG ; Da Hee KIM ; Su Jin KANG ; Sun Ok PARK ; Dong Hyun CHA
Journal of Genetic Medicine 2014;11(1):16-21
A 31-year-old woman, who was pregnant with twins, underwent chorionic villus sampling because of increased nuchal translucency in one of the fetuses. Cytogenetic analysis showed a normal karyotype in the fetus with increased nuchal translucency. However, the other fetus, with normal nuchal translucency, had a derivative X chromosome (der(X)). For further analysis, fluorescence in situ hybridization (FISH) and additional molecular studies including fragile X analysis were performed. FISH analysis confirmed that the Y chromosome was the origin of extra segment of the der(X). The X-chromosome breakpoint was determined to be at Xq27 by FMR1 CGG repeat analysis, and the Y-chromosome breakpoint was determined to be at Yq11.23 by the Y chromosome microdeletion study. To predict the fetal outcome, the X-inactivation pattern was examined, and it revealed non-random X inactivation of the der(X). To the best of our knowledge, the identification of an unbalanced Xq;Yq translocation at prenatal diagnosis has never been reported. This study was performed to identify precise breakpoints and the X-inactivation pattern as well as to provide the parents with appropriate genetic counseling.
Adult
;
Chorionic Villi Sampling
;
Cytogenetic Analysis
;
Female
;
Fetus*
;
Fluorescence
;
Genetic Counseling
;
Humans
;
In Situ Hybridization
;
Karyotype
;
Nuchal Translucency Measurement
;
Parents
;
Pregnancy
;
Prenatal Diagnosis
;
Twins
;
X Chromosome
;
X Chromosome Inactivation
;
Y Chromosome
9.Epigenetic Alterations of IL-6/STAT3 Signaling by Placental Stem Cells Promote Hepatic Regeneration in a Rat Model with CCl4-induced Liver Injury.
Jieun JUNG ; Ji Wook MOON ; Jong Ho CHOI ; Yong Woo LEE ; Sun Hwa PARK ; Gi Jin KIM
International Journal of Stem Cells 2015;8(1):79-89
BACKGROUND: Human chorionic plate-derived mesenchymal stem cells (CP-MSCs) isolated from the placenta have been reported to demonstrate therapeutic effects in animal models of liver injury; however, the underlying epigenetic mechanism of this effect has not been elucidated. Thus, we investigated whether CP-MSCs influence epigenetic processes during regeneration of the injured liver. METHODS: CP-MSCs were engrafted into a carbon tetrachloride (CCl4)-injured rat model through direct transplantation into the liver (DTX), intrasplenic transplantation (STX), and intravenous transplantation via the tail vein (TTX). Non-transplanted (NTX) rats were maintained as sham controls. Liver tissues were analyzed after transplantation using immunohistochemistry, western blot analysis, and quantitative methylation-specific polymerase chain reaction. Proliferation and human interleukin-6 (hIL-6) enzyme-linked immunosorbent assays were performed using CCl4-treated hepatic cells that were co-cultured with CP-MSCs. RESULTS: The Ki67 labeling index, cell cyclins, albumin, IL-6, and gp130 levels were elevated in the CP-MSC transplantation groups. The concentration of hIL-6 in supernatants and the proliferation of CCl4-treated rat hepatic cells were enhanced by co-culturing with CP-MSCs (p<0.05), while the methylation of IL-6/IL-6R and STAT3 by CP-MSC transplantation decreased. CONCLUSION: These results suggest that administration of CP-MSCs promotes IL-6/STAT3 signaling by decreasing the methylation of the IL-6/SATA3 promoters and thus inducing the proliferation of hepatic cells in a CCl4-injured liver rat model. These data advance our understanding of the therapeutic mechanisms in injured livers, and can facilitate the development of cell-based therapies using placenta-derived stem cells.
Animals
;
Blotting, Western
;
Carbon Tetrachloride
;
Chorion
;
Cyclins
;
DNA Methylation
;
Enzyme-Linked Immunosorbent Assay
;
Epigenesis, Genetic
;
Epigenomics*
;
Hepatocytes
;
Humans
;
Immunohistochemistry
;
Interleukin-6
;
Liver Regeneration
;
Liver*
;
Mesenchymal Stromal Cells
;
Methylation
;
Models, Animal*
;
Placenta
;
Polymerase Chain Reaction
;
Rats
;
Regeneration*
;
Stem Cells*
;
Veins
10.Medial Trunk Aneurysm of the Distal Posterior Inferior Cerebellar Artery in the Fourth Ventricle: Case Report.
Jung Yong AHN ; Young Sun CHUNG ; Ok Jun KIM ; Sung Wook CHOI
Journal of Korean Neurosurgical Society 2003;34(1):57-60
We present a case of a ruptured aneurysm of the medial trunk of the right posterior inferior cerebellar artery(PICA) in the fourth ventricle. A 52-year-old man presented with sudden onset of headache, followed by an abrupt decline in consciousness. Angiographic studies revealed that the aneurysm arose from the medial trunk of the right PICA, distal to the choroidal point and associated with the stenosis of the basilar artery and the hypoplasia of the right anterior inferior cerebellar artery and superior cerebellar artery. The patient underwent a midline suboccipital craniotomy and aneurysmectomy after clipping of the parent artery. A postoperative angiogram confirmed complete obliteration of the aneurysm, but demonstrated occlusion of the vermian branch of the right PICA. The pathogenesis of this lesion could be due to hemodynamic stress.
Aneurysm*
;
Aneurysm, Ruptured
;
Arteries*
;
Basilar Artery
;
Choroid
;
Consciousness
;
Constriction, Pathologic
;
Craniotomy
;
Fourth Ventricle*
;
Headache
;
Hemodynamics
;
Humans
;
Intracranial Aneurysm
;
Middle Aged
;
Parents
;
Pica